Cargando…
Patient-reported barriers to osteoporosis therapy
SUMMARY: We investigated reasons for non-treatment of osteoporosis and discontinuation of osteoporosis therapy. Barriers to treatment include patients’ preference for alternative treatments and a fear of possible side effects. Side effects are a common reason for treatment discontinuation, and they...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer London
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4851700/ https://www.ncbi.nlm.nih.gov/pubmed/27129487 http://dx.doi.org/10.1007/s11657-016-0272-5 |
_version_ | 1782429847340974080 |
---|---|
author | Lindsay, Brianna R. Olufade, Temitope Bauer, Jennifer Babrowicz, Jane Hahn, Rebecca |
author_facet | Lindsay, Brianna R. Olufade, Temitope Bauer, Jennifer Babrowicz, Jane Hahn, Rebecca |
author_sort | Lindsay, Brianna R. |
collection | PubMed |
description | SUMMARY: We investigated reasons for non-treatment of osteoporosis and discontinuation of osteoporosis therapy. Barriers to treatment include patients’ preference for alternative treatments and a fear of possible side effects. Side effects are a common reason for treatment discontinuation, and they may be associated with a lack of willingness to restart treatment. PURPOSE/INTRODUCTION: Osteoporosis patients commonly cite treatment-related side effects, or the fear thereof, as a reason for discontinuing or not initiating anti-osteoporosis medications. The purpose of this study was to investigate, from the patient’s perspective, reasons for (i) non-treatment of osteoporosis and (ii) discontinuation of osteoporosis therapy. METHODS: This was an internet-based survey of postmenopausal women in the USA who self-reported having been diagnosed with osteoporosis. Respondents were recruited from consumer research panels and received nominal compensation. RESULTS: Within the surveyed population (N = 1407), 581 patients were currently being treated, 503 had never been treated, and 323 had previously been treated. Among patients never treated for osteoporosis, the highest ranking reasons for non-treatment were the use of alternative treatments such as over-the-counter vitamins/supplements (57.5 % of respondents) and fear of side effects (43.9 %). Among previously treated patients, frequent reasons for discontinuation included the direction of the physician (41.2 % of respondents), concerns about long-term safety (30.3 %), and the experience of side effects (29.8 %). When asked about their willingness to restart their osteoporosis medication, previously treated patients who were not willing (N = 104) to restart had a higher frequency of experiencing side effects (44.2 versus 20.5 % of those willing; P < 0.001). CONCLUSIONS: From the osteoporosis patient’s perspective, barriers to prescription treatment include a preference for alternative, non-prescription treatments and a fear of possible side effects. Side effects are one of the most common reasons for discontinuing osteoporosis medications, and they appear to be associated with a lack of willingness to restart treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11657-016-0272-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4851700 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer London |
record_format | MEDLINE/PubMed |
spelling | pubmed-48517002016-05-19 Patient-reported barriers to osteoporosis therapy Lindsay, Brianna R. Olufade, Temitope Bauer, Jennifer Babrowicz, Jane Hahn, Rebecca Arch Osteoporos Original Article SUMMARY: We investigated reasons for non-treatment of osteoporosis and discontinuation of osteoporosis therapy. Barriers to treatment include patients’ preference for alternative treatments and a fear of possible side effects. Side effects are a common reason for treatment discontinuation, and they may be associated with a lack of willingness to restart treatment. PURPOSE/INTRODUCTION: Osteoporosis patients commonly cite treatment-related side effects, or the fear thereof, as a reason for discontinuing or not initiating anti-osteoporosis medications. The purpose of this study was to investigate, from the patient’s perspective, reasons for (i) non-treatment of osteoporosis and (ii) discontinuation of osteoporosis therapy. METHODS: This was an internet-based survey of postmenopausal women in the USA who self-reported having been diagnosed with osteoporosis. Respondents were recruited from consumer research panels and received nominal compensation. RESULTS: Within the surveyed population (N = 1407), 581 patients were currently being treated, 503 had never been treated, and 323 had previously been treated. Among patients never treated for osteoporosis, the highest ranking reasons for non-treatment were the use of alternative treatments such as over-the-counter vitamins/supplements (57.5 % of respondents) and fear of side effects (43.9 %). Among previously treated patients, frequent reasons for discontinuation included the direction of the physician (41.2 % of respondents), concerns about long-term safety (30.3 %), and the experience of side effects (29.8 %). When asked about their willingness to restart their osteoporosis medication, previously treated patients who were not willing (N = 104) to restart had a higher frequency of experiencing side effects (44.2 versus 20.5 % of those willing; P < 0.001). CONCLUSIONS: From the osteoporosis patient’s perspective, barriers to prescription treatment include a preference for alternative, non-prescription treatments and a fear of possible side effects. Side effects are one of the most common reasons for discontinuing osteoporosis medications, and they appear to be associated with a lack of willingness to restart treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11657-016-0272-5) contains supplementary material, which is available to authorized users. Springer London 2016-04-29 2016 /pmc/articles/PMC4851700/ /pubmed/27129487 http://dx.doi.org/10.1007/s11657-016-0272-5 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Lindsay, Brianna R. Olufade, Temitope Bauer, Jennifer Babrowicz, Jane Hahn, Rebecca Patient-reported barriers to osteoporosis therapy |
title | Patient-reported barriers to osteoporosis therapy |
title_full | Patient-reported barriers to osteoporosis therapy |
title_fullStr | Patient-reported barriers to osteoporosis therapy |
title_full_unstemmed | Patient-reported barriers to osteoporosis therapy |
title_short | Patient-reported barriers to osteoporosis therapy |
title_sort | patient-reported barriers to osteoporosis therapy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4851700/ https://www.ncbi.nlm.nih.gov/pubmed/27129487 http://dx.doi.org/10.1007/s11657-016-0272-5 |
work_keys_str_mv | AT lindsaybriannar patientreportedbarrierstoosteoporosistherapy AT olufadetemitope patientreportedbarrierstoosteoporosistherapy AT bauerjennifer patientreportedbarrierstoosteoporosistherapy AT babrowiczjane patientreportedbarrierstoosteoporosistherapy AT hahnrebecca patientreportedbarrierstoosteoporosistherapy |